ANI Pharmaceuticals, Inc. (ANIP) Earnings Call Transcripts

ANI Pharmaceuticals, Inc.'s Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, ANI Pharmaceuticals, Inc. reported total net revenues of $237.5 million, reflecting a 20% year-over-year increase. Adjusted EBITDA grew by 24% to $63 million, and the company raised its full-year revenue guidance to a range of $1.08 billion to $1.14 billion, up $25 million from previous expectations. The strong performance was driven by growth in the Rare Disease and Generics segments, particularly Cortrophin Gel, which saw a 42% increase in revenues to $75.1 million.

Reported metrics

Guidance from management

ANI raised its 2026 revenue guidance to $1.08 billion to $1.14 billion and adjusted EBITDA guidance to $285 million to $300 million, reflecting strong first quarter performance and confidence in future growth.

What management said

Thank you, Steve. Turning to Slide 16. In closing, we are making meaningful progress against our strategic priorities to accelerate our transformation into a leading Rare Disease company, continuing to execute in Generics and deploying capital in a disciplined manner. Overall, we expect to deliver over $1 billion in revenue in '26 with Rare Disease representing approximately 60% of total revenues. We are on track to ...

Yes. So on the Harmony royalties, the royalty is due on all pitolisant products, including WAKIX, and any future products that may be introduced that is pitolisant based. And in terms of whether we would sell that royalty stream or not, we typically don't discuss any potential future BD. At the moment, we're just very pleased with the collaboration with Harmony and look forward to executing our portion of that out-li...

What analysts pressed on

Analysts expressed concerns regarding the disconnect between prescription growth data and reported revenues for Cortrophin. There were also inquiries about the impact of payer dynamics and potential changes in rebates for 2026 compared to 2025.

Main topics on the call

• Revenue Growth Acceleration — ANI achieved total net revenues of $237.5 million in Q1 2026, a 20% increase year-over-year. Management noted, "These strong first quarter results enabled us to raise our 2026 financial guidance for total revenue to the ...
• Cortrophin Gel Performance — Cortrophin Gel revenues reached $75.1 million, up 42% year-over-year. Management indicated that "we saw an acceleration in February and March, which carried into April," suggesting strong momentum in the second quarter.
• Generics Business Strength — The Generics segment reported revenues of $105.4 million, a 7% increase over the prior year. Management highlighted, "We are able to report meaningful progress on this front," indicating ongoing operational improvements.
• Guidance Increase — The company raised its 2026 revenue guidance by $25 million, now expecting $1.08 billion to $1.14 billion. Adjusted EBITDA guidance was also increased to $285 million to $300 million, reflecting confidence in future perf...

Read the full ANI Pharmaceuticals, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 34 ANI Pharmaceuticals, Inc. earnings call transcripts on record, spanning February 27, 2020 to August 7, 2026. Based on this history, ANI Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated August 7, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ANIP

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

34

First call

February 27, 2020

Most recent

August 7, 2026

Reporting cadence

quarterly